Regenerex Pharma, Inc. has announced a significant change in its financial oversight by appointing Rosenfield and Company PLLC CPA of Corinth, Texas, as its new independent registered public accounting firm. This decision, finalized by the company’s Board of Directors on October 28, 2026, is expected to enhance the company's compliance with reporting obligations.
The appointment comes at a crucial time for Regenerex, as it seeks to bring its past due Form-10Q filings up to date. The new accounting firm is currently preparing these filings, indicating a proactive approach to address previous delays in reporting.
Background
Regenerex Pharma, Inc., classified under the Standard Industrial Classification (SIC) code 2834, operates within the pharmaceutical preparations industry. The company has undergone several name changes in its history, with its most recent name change occurring in March 2018 when it transitioned from Peptide Technologies, Inc. The company is incorporated in Nevada and has been classified as an emerging growth company.
What the Filing Says
The filing, dated November 16, 2026, reveals that the engagement letter with Rosenfield and Company became effective on October 26, 2026. The document states, "The new independent registered public accounting firm is currently preparing the company’s past due Form-10Q filings to bring the company current with its reporting obligations." This highlights the urgency and importance of the new partnership in enhancing Regenerex's financial reporting.
Impact
This change in accounting firms may significantly affect Regenerex’s stakeholders, including investors and regulatory bodies, as it aims to improve transparency and compliance. The pharmaceutical preparations industry, which is often under scrutiny for regulatory compliance, may also feel the ripple effects of Regenerex's commitment to better governance.
What's Next
The filing does not specify what happens next, but the focus on completing overdue filings suggests that Regenerex is prioritizing compliance and transparency in its financial reporting.
This strategic move is likely to position Regenerex more favorably within the industry, as it aligns with broader trends towards improved governance and accountability in the pharmaceutical sector.
Read Next
Kidoz Inc. to Release Q3 2026 Results and Hold AGM
NuRAN Wireless Receives Nasdaq Notification on Stock Price
Lincoln National to Restate Financial Statements Following Error
Freeport-McMoRan plans senior notes offering to refinance debt
Cadre Holdings CFO Blaine Browers to Resign; Appleby Named Interim
Nasus Pharma appoints Nir Sassi as Chief Financial Officer









